Novel Diabetes Drugs and the Cardiovascular Specialist

Journal of the American College of Cardiology

Volumn 69, Issue 21, 2017, Pages 2646-2656

  Sattar, Naveed ^a   Petrie, Mark C ^a   Zinman, Bernard ^b   Januzzi, James L ^c,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

blood glucose; cardiovascular disease; heart failure; hypoglycemic agents; outcomes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; GLUCOSE BLOOD LEVEL;

ACUTE CORONARY SYNDROME; BLADDER CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETIC KETOACIDOSIS; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FLUID RETENTION; FRACTURE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PREMATURE MORTALITY; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY; RISK FACTOR; SURVIVAL RATE; TRENDS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SURVIVAL RATE;

EID: 85019611136     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.04.014     Document Type: Review

References (53)

1. Hirshberg, B., Katz, A., Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care 36:Suppl 2 (2013), S253–S258.
2. Zinman, B., Wanner, C., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
4. Marso, S.P., Bain, S.C., Consoli, A., et al., for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
6. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000), 145–153.
7. Turnbull, F.M., Abraira, C., Anderson, R.J., et al., for the Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
8. Ray, K.K., Seshasai, S.R.K., Wijesuriya, S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
9. Simpson, S.H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A.S., Featherstone, T.R., Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3 (2015), 43–51.
10. Bain, S., Druyts, E., Balijepalli, C., et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab 19 (2017), 329–335.
11. Hemmingsen, B., Schroll, J.B., Lund, S.S., et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev, 4, 2013, CD009008.
12. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
13. Levin, D., Bell, S., Sund, R., et al., for the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58 (2015), 493–504.
14. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357 (2007), 28–38.
15. Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11 (2011), 115–128.
16. Stone, J.C., Furuya-Kanamori, L., Barendregt, J.J., Doi, S.A.R., Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?. Pharmacoepidemiol Drug Saf 24 (2015), 223–227.
17. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., et al., for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
18. Cariou, B., Charbonnel, B., Staels, B., Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 23 (2012), 205–215.
19. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
20. White, W.B., Cannon, C.P., Heller, S.R., et al., for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
21. Green, J.B., Bethel, M.A., Armstrong, P.W., et al., for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
22. Wu, D., Li, L., Liu, C., Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 16 (2014), 30–37.
23. Rehman, M.B., Tudrej, B.V., Soustre, J., et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab 43 (2017), 48–58.
24. McGuire, D.K., Van de Werf, F., Armstrong, P.W., et al., for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
25. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
27. U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [news release]. December 2, 2016. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed April 5, 2017.
28. Boehringer Ingelheim, Eli Lilly and Company. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT03057951. Accessed April 5, 2017.
29. Boehringer Ingelheim, Eli Lilly and Company. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available at: https://clinicaltrials.gov/ct2/show/NCT03057977. Accessed April 5, 2017.
30. AstraZeneca. AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure [press release]. September 12, 2016. Available at: https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-two-new-phase-IIIb-trials-for-Forxiga-in-chronic-kidney-disease-and-chronic-heart-failure-120920161.html. Accessed April 5, 2017.
31. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
32. Cherney, D.Z.I., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
33. Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG OUTCOMEs surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
34. Heerspink, H.J.L., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z.I., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
35. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37 (2016), 3192–3200.
36. Verma, S., Garg, A., Yan, A.T., et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial?. Diabetes Care 39 (2016), e212–e213.
37. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
38. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
39. MacDonald, M.R., Petrie, M.C., Hawkins, N.M., et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29 (2008), 1224–1240.
40. Drucker, D.J., The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24 (2016), 15–30.
41. Holman, R.R., Bethel, M.A., George, J., et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 174 (2016), 103–110.
42. Pfeffer, M.A., Claggett, B., Diaz, R., et al., for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
43. Gregg, E.W., Sattar, N., Ali, M.K., The changing face of diabetes complications. Lancet Diabetes Endocrinol 4 (2016), 537–547.
44. Dinesh Shah, A., Langenberg, C., Rapsomaniki, E., et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1·9 million people. Lancet, 385(Suppl 1), 2015, S86.
45. Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA 314 (2015), 52–60.
46. Fang, J.C., Heart failure with preserved ejection fraction: a kidney disorder?. Circulation 134 (2016), 435–437.
47. Suskin, N., McKelvie, R.S., Burns, R.J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21 (2000), 1368–1375.
48. Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
49. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 40 (2016), 484–486.
50. Petrie, J.R., The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol, 12, 2013, 130.
51. Everett, B.M., Brooks, M.M., Vlachos, H.E.A., Chaitman, B.R., Frye, R.L., Bhatt, D.L., for the BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 373 (2015), 610–620.
52. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 989–998.
53. Preiss, D., Sattar, N., Research digest: cardiac biomarkers for risk prediction. Lancet Diabetes Endocrinol, 4, 2016, 890.